Aims: To evaluate the cardiovascular efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in Asian, Black or African American, and White populations, and to assess whether the magnitude of cardiovascular risk reduction differs across these populations.
For survivors, the journey is fraught with risks, including the likelihood of a second stroke or a heart attack, which affects nearly one in four stroke survivors. Emerging research suggests that certain type 2 diabetes medications, specifically GLP-1 receptor agonists and SGLT2 inhibitors...
GLP-1 Receptor Activation: GLP-1 agonists bind to and activate GLP-1 receptors, which are widely distributed in tissues including the pancreas, brain, and gastrointestinal tract. These receptors are pivotal in regulating insulin secretion, glucose metabolism, and appetite.
GLP-1 receptor agonists have emerged as biologically plausible modulators of reward circuitry and addictive behavior. Preclinical data are robust and consistent across substances, while human evidence provides encouraging but non-causal signals.
Synthetic GLP-1 receptor agonists are variably resistant to degradation by the enzyme DPP-4, and therefore have a longer half-life, facilitating clinical use. Longer-acting GLP-1 receptor agonists can be administered once daily or once weekly.
